<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <actions>
      <actionTypeCounts>
        <introducedInTheHouse>1</introducedInTheHouse>
        <introducedInHouse>1</introducedInHouse>
        <placeholderTextForB>1</placeholderTextForB>
        <billReferrals>1</billReferrals>
      </actionTypeCounts>
      <actionByCounts>
        <houseOfRepresentatives>3</houseOfRepresentatives>
      </actionByCounts>
      <item>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <committee>
          <systemCode>hsif00</systemCode>
          <name>Energy and Commerce Committee</name>
        </committee>
        <links />
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
        <type>IntroReferral</type>
        <actionDate>2016-07-14</actionDate>
      </item>
      <item>
        <text>Sponsor introductory remarks on measure. (CR E1133)</text>
        <committee />
        <links>
          <link>
            <url>https://www.congress.gov/congressional-record/volume-162/extensions-of-remarks-section/page/E1133</url>
            <name>E1133</name>
          </link>
        </links>
        <actionCode>B00100</actionCode>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <type>IntroReferral</type>
        <actionDate>2016-07-14</actionDate>
      </item>
      <item>
        <text>Introduced in House</text>
        <committee />
        <links />
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <type>IntroReferral</type>
        <actionDate>2016-07-14</actionDate>
      </item>
      <item>
        <text>Introduced in House</text>
        <committee />
        <links />
        <actionCode>1000</actionCode>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
        <type>IntroReferral</type>
        <actionDate>2016-07-14</actionDate>
      </item>
    </actions>
    <updateDate>2017-10-27T18:05:52Z</updateDate>
    <introducedDate>2016-07-14</introducedDate>
    <recordedVotes />
    <createDate>2016-07-15T07:14:36Z</createDate>
    <congress>114</congress>
    <sponsors>
      <item>
        <firstName>Michael</firstName>
        <lastName>McCaul</lastName>
        <state>TX</state>
        <bioguideId>M001157</bioguideId>
        <party>R</party>
        <identifiers>
          <bioguideId>M001157</bioguideId>
          <gpoId>8166</gpoId>
          <lisID>1804</lisID>
        </identifiers>
        <byRequestType />
        <middleName>T.</middleName>
        <fullName>Rep. McCaul, Michael T. [R-TX-10]</fullName>
        <district>10</district>
      </item>
    </sponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <titles>
      <item>
        <parentTitleType />
        <titleType>Short Titles as Introduced</titleType>
        <title>RACE for Children Act</title>
        <chamberName />
        <chamberCode />
      </item>
      <item>
        <parentTitleType />
        <titleType>Short Titles as Introduced</titleType>
        <title>Research to Accelerate Cures and Equity for Children Act</title>
        <chamberName />
        <chamberCode />
      </item>
      <item>
        <parentTitleType />
        <titleType>Official Title as Introduced</titleType>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to establish a program to provide additional incentives for the development of new drugs to treat pediatric cancers, and for other purposes.</title>
        <chamberName />
        <chamberCode />
      </item>
      <item>
        <parentTitleType />
        <titleType>Display Title</titleType>
        <title>RACE for Children Act</title>
        <chamberName />
        <chamberCode />
      </item>
    </titles>
    <amendments />
    <version>1.0.0</version>
    <cosponsors>
      <item>
        <bioguideId>B001251</bioguideId>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <party>D</party>
        <sponsorshipWithdrawnDate />
        <state>NC</state>
        <firstName>G. K.</firstName>
        <identifiers>
          <lisID>1761</lisID>
          <bioguideId>B001251</bioguideId>
          <gpoId>8024</gpoId>
        </identifiers>
        <fullName>Rep. Butterfield, G. K. [D-NC-1]</fullName>
        <district>1</district>
        <sponsorshipDate>2016-07-14</sponsorshipDate>
        <lastName>Butterfield</lastName>
        <middleName />
      </item>
      <item>
        <bioguideId>D000614</bioguideId>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <party>R</party>
        <sponsorshipWithdrawnDate />
        <state>WI</state>
        <firstName>Sean</firstName>
        <identifiers>
          <gpoId>8220</gpoId>
          <lisID>2072</lisID>
          <bioguideId>D000614</bioguideId>
        </identifiers>
        <fullName>Rep. Duffy, Sean P. [R-WI-7]</fullName>
        <district>7</district>
        <sponsorshipDate>2016-07-14</sponsorshipDate>
        <lastName>Duffy</lastName>
        <middleName>P.</middleName>
      </item>
      <item>
        <bioguideId>V000128</bioguideId>
        <isOriginalCosponsor>True</isOriginalCosponsor>
        <party>D</party>
        <sponsorshipWithdrawnDate />
        <state>MD</state>
        <firstName>Chris</firstName>
        <identifiers>
          <bioguideId>V000128</bioguideId>
          <gpoId>7983</gpoId>
          <lisID>1729</lisID>
        </identifiers>
        <fullName>Rep. Van Hollen, Chris [D-MD-8]</fullName>
        <district>8</district>
        <sponsorshipDate>2016-07-14</sponsorshipDate>
        <lastName>Van Hollen</lastName>
        <middleName />
      </item>
      <item>
        <bioguideId>L000563</bioguideId>
        <isOriginalCosponsor>False</isOriginalCosponsor>
        <party>D</party>
        <sponsorshipWithdrawnDate />
        <state>IL</state>
        <firstName>Daniel</firstName>
        <identifiers>
          <lisID>1781</lisID>
          <bioguideId>L000563</bioguideId>
          <gpoId>7923</gpoId>
        </identifiers>
        <fullName>Rep. Lipinski, Daniel [D-IL-3]</fullName>
        <district>3</district>
        <sponsorshipDate>2016-11-18</sponsorshipDate>
        <lastName>Lipinski</lastName>
        <middleName>William</middleName>
      </item>
    </cosponsors>
    <constitutionalAuthorityStatementText><![CDATA[<pre>From the Congressional Record Online through the Government Publishing Office [<a href='http://www.gpo.gov'>www.gpo.gov</a>]By Mr. McCAUL:H.R. 5858.Congress has the power to enact this legislation pursuantto the following:Article 1, Section 8, Clauses 3 and 18 of the Constitution[Page H5014]</pre>]]></constitutionalAuthorityStatementText>
    <billType>HR</billType>
    <committeeReports />
    <notes />
    <subjects>
      <billSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
        <legislativeSubjects>
          <item>
            <name>Cancer</name>
          </item>
          <item>
            <name>Child health</name>
          </item>
          <item>
            <name>Drug safety, medical device, and laboratory regulation</name>
          </item>
          <item>
            <name>Drug therapy</name>
          </item>
          <item>
            <name>Medical research</name>
          </item>
        </legislativeSubjects>
      </billSubjects>
    </subjects>
    <committees>
      <billCommittees>
        <item>
          <name>Energy and Commerce Committee</name>
          <chamber>House</chamber>
          <activities>
            <item>
              <name>Referred to</name>
              <date>2016-07-14T13:08:30Z</date>
            </item>
          </activities>
          <type>Standing</type>
          <subcommittees />
          <systemCode>hsif00</systemCode>
        </item>
      </billCommittees>
    </committees>
    <latestAction>
      <actionDate>2016-07-14</actionDate>
      <text>Referred to the House Committee on Energy and Commerce.</text>
      <links />
    </latestAction>
    <relatedBills>
      <item>
        <number>3239</number>
        <congress>114</congress>
        <type>S</type>
        <latestTitle>RACE for Children Act</latestTitle>
        <relationshipDetails>
          <item>
            <identifiedBy>CRS</identifiedBy>
            <type>Identical bill</type>
          </item>
        </relationshipDetails>
        <latestAction>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
          <actionDate>2016-07-14</actionDate>
        </latestAction>
      </item>
    </relatedBills>
    <laws />
    <originChamber>House</originChamber>
    <cboCostEstimates />
    <title>RACE for Children Act</title>
    <summaries>
      <billSummaries>
        <item>
          <lastSummaryUpdateDate>2017-01-04T14:53:37Z</lastSummaryUpdateDate>
          <versionCode>00</versionCode>
          <actionDate>2016-07-14</actionDate>
          <text><![CDATA[<p><b>Research to Accelerate Cures and Equity for Children Act or the RACE for Children Act</b></p> <p>This bill amends the Federal Food, Drug, and Cosmetic Act to expand requirements for assessing the use of medications in pediatric populations.</p> <p>Applications and supplements to applications for certain drugs and biological products, including orphan drugs, that could be used to treat pediatric cancer must include an assessment of pediatric use. Upon request, the Food and Drug Administration (FDA) must meet with the sponsor of such a medication to discuss the plan for pediatric studies.</p> <p>The FDA may require the sponsor of an approved medication that could be used to treat pediatric cancer to complete a pediatric assessment if: (1) the medication is used for a substantial number of pediatric cancer patients, or (2) there is reason to believe the medication would have a meaningful therapeutic benefit over existing therapies for pediatric cancer patients.</p> <p>The bill limits waivers of pediatric assessment requirements for certain medications that could be used to treat a pediatric cancer for which there is a need for additional treatment options.</p> The FDA must meet with medication sponsors to discuss a deferral or waiver of the pediatric assessment requirement.]]></text>
          <actionDesc>Introduced in House</actionDesc>
          <updateDate>2016-07-14T04:00:00Z</updateDate>
          <name>Introduced in House</name>
        </item>
      </billSummaries>
    </summaries>
    <calendarNumbers />
    <billNumber>5858</billNumber>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

